Physicians' Academy for Cardiovascular Education

Heart Failure

Follow the news, literature, and elearning on new developments in the management of Heart Failure.

Getting better at diagnosing HFpEF - sharing clinical practice experience

15' education - July 28, 2020 - Prof. Mark Petrie, MD and Pardeep Jhund, MD, PhD

Improving outcomes for patients following an admission with ADHF

15' education - July 7, 2020 - Prof. Mark Petrie, MD and Klaus Witte, MD

Diabetes and CKD: is it all about managing glucose?

10' education - July 1, 2020 - Prof. Melanie Davies, MD
Lecture 1 out of 3

COVID-19, ACE2 and RAASi - a scientific perspective

10' education - Apr. 19, 2020 - Prof. Jan Danser, PhD
Lecture 2 out of 3

A clinical perspective on COVID-19, ACE2 and RAAS inhibition

10' education - Apr. 18, 2020 - Prof. Murray Epstein, MD
Lecture (panel discussion) 3 out of 3

COVID-19, ACE2 and RAAS inhibition: What are the implications for practice?

10' education - Apr. 17, 2020 - Profs. John Deanfield, Jan Danser and Murray Epstein

Use of ARNI in HFpEF patients reduces NT-proBNP levels

3' education - Apr. 8, 2020 - Jonathan Cunningham, MD

Added value of sGC stimulator in worsening HFrEF patients

3' education - Mar. 31, 2020 - Prof. Paul Armstrong, MD - ACC 2020

HFpEF: A misunderstood disease in search of a therapy

10' education - Jan. 23, 2020 - Prof. Scott Solomon

Effects of ARNI treatment on arterial hemodynamics, cardiac remodelling and pulmonary artery pressure in HFrEF

5' education - Jan. 14, 2020 - Akshay S. Desai, MD

Heart failure with mid-range ejection fraction

10' education - Jan. 6, 2020 - Prof. Burkert Pieske, MD

Efficacy and safety of ARNI in high-risk patients in the PIONEER-HF trial

5' education - Dec. 19, 2019 - Prof. David Morrow, MD

PARADIGM-HF and PARAGON-HF: Redefining HFrEF and HFpEF

10' education - Dec. 10, 2019 - Milton Packer, MD

Is HF the same disease across the EF spectrum, or does HF have two physiologies that respond differently to treatment?

3' education - Nov. 18, 2019 - Prof. Lynne Stevenson - AHA 2019, Philadelphia

ARNI seems to give CV benefit not only in HFrEF, but up to EF of about 60%

3' education - Nov. 18, 2019 - Prof. Scott Solomon - AHA 2019, Philadelphia

Consistent CV benefit and tolerability of SGLT2i in HF patients irrespective of diabetes

3' education - Nov. 16, 2019 - John McMurray, MD, Glasgow - AHA 2019, Philadelphia

Betablocker use associated with reduced mortality in HFrEF patients >80 years

5' education - Oct. 22, 2019 - Paris, France - Gianluigi Savarese, MD

NP metabolism associated with clinical outcomes in HF

5' education - Oct. 15, 2019 - Frank Gommans, MD, PhD

Heart Failure: What are the practical consequences of current and ongoing SGLT2i outcome trials?

10' education - Oct. 15, 2019 - Prof. Faiez Zannad, MD

A revolution in treatment of HFrEF with a SGLT2 inhibitor

5' education - Sep. 1, 2019 - Paris, France - Prof. Subodh Verma, MD, PhD

Heart & Kidney interactions: What are the challenges for prevention and protection?

10' education - Sep. 2, 2019 - Prof. Christoph Wanner

The 2019 ESC/EASD diabetes guidelines: a major paradigm shift in the management of T2DM

10' education - Sep. 30, 2019 - Paris, France - Prof. Francesco Cosentino, MD

Cardioprotective mechanisms of SGLT2 inhibitors: What do cardiologists need to know?

10' education - Sep. 24, 2019 - Prof. Nikolaus Marx, MD

Almost significant effects on CV outcomes with ARNI in HFpEF

3' education - Sep. 23, 2019 - Paris, France - Prof. Dirk Jan van Veldhuisen, MD

Early and sustained vasodilation strategy fails to improve outcomes in acute HF

3' education - Sep. 2, 2019 - Prof. Christian Müller

Large risk reductions with SGLT2 inhibitor in HFrEF with or without diabetes

3' education - Sep. 1, 2019 - Paris, France - Prof. John McMurray

ARNI treatment in HFpEF shows benefit in secondary outcomes, but misses significance in primary endpoint

3' education - Sep. 1, 2019 - Prof. Scott Solomon

Incident hyperkalemia, RAASi use and outcomes in acute hospitalized HF patients

5' education - Aug. 26, 2019 - Joost Beusekamp

A novel parameter for proximal tubular function in HF

5' education - Aug. 21, 2019 - Lisa Emmens

Addressing the risk of hyperkalemia in HF: is there a sweet spot for potassium binding?

10' education - Aug. 21, 2019 - Prof. van der Meer, MD, PhD - Online CME

sGC stimulator gets priority review by FDA for HFrEF treatment

News - July 30, 2020

The FDA has accepted the new drug application for vericiguat for priority review. The sGC stimulator vericiguat is under development for the treatment of patients with chronic HF with ejection fraction <45%.

SGLT2i efficacious and safe regardless of baseline ARNI treatment in HFrEF

Literature - July 29, 2020 - Solomon SD et al., - J Am Coll Cardiol Heart Fail. 2020.

In HFrEF patients from the DAPA-HF trial, the SGLT2 inhibitor dapagliflozin was similarly efficacious and safe in those receiving ARNI treatment and those not receiving ARNI treatment.

Getting better at diagnosing HFpEF - sharing clinical practice experience

15' education - July 28, 2020 - Prof. Mark Petrie, MD and Pardeep Jhund, MD, PhD
Two heart failure specialists from Glasgow, UK discuss a patient case to demonstrate that it can be difficult to diagnose HFpEF. They present tools that can help in the process of diagnosing HFpEF.

Two heart failure specialists from Glasgow, UK discuss a patient case to demonstrate that it can be difficult to diagnose HFpEF. They present tools that can help in the process of diagnosing HFpEF.

HF development after T2DM diagnosis associated with highest 5-year risk of death

Literature - July 21, 2020 - Zareini B et al., - Circ Cardiovasc Qual Outcomes. 2020.

T2DM patients who developed HF alone or in combination with stroke, CKD or PAD had the highest 5-year risk of death and the greatest decrease in lifespan when compared with development of other CV and renal diseases.

HFA publishes position paper on SGLT2i in heart failure

News - July 15, 2020

The Heart Failure Association of the ESC has recently published a position paper on SGLT2i therapy in heart failure, beyond glycemic control.

A scientific statement of AHA on amyloidosis

News - July 13, 2020

The American Heart Association has published a scientific statement covering diagnosis and management of transthyretin amyloid cardiomyopathy (ATTR-CM).

Improving outcomes for patients following an admission with ADHF

15' education - July 7, 2020 - Prof. Mark Petrie, MD and Klaus Witte, MD

Using a case of a heart failure (HF) patient who was admitted to the hospital with acute decompensated HF (ADHF), two specialists discuss what the optimal treatment strategy in hospitalized patients should be during time of admission.

LVEF deterioration into midrange levels increases risk of adverse outcomes in HFmrEF

Literature - July 2, 2020 - Brann A et al., - JAMA Cardiol. 2020.

Patients whose LVEF deteriorated from normal to midrange levels had a significantly higher risk of adverse clinical outcomes compared to those whose LVEF had improved from lower values.

Diabetes and CKD: is it all about managing glucose?

10' education - July 1, 2020 - Prof. Melanie Davies, MD
Prof. Davies talks about the interrelationship between T2DM, CVD (including heart failure) and CKD and how treatment with GLP-1RAs affects these interrelated systems.

Prof. Davies talks about the interrelationship between T2DM, CVD (including heart failure) and CKD and how treatment with GLP-1RAs affects these interrelated systems.

No effect of soluble guanylate cyclase stimulator on functional capacity in HFpEF

News - June 30, 2020

HFA Discoveries 2020 Despite promising preclinical findings and pathophysiologic rationale, the sGC stimulator praliciguat did not result in a difference in change in peak VO₂ compared to placebo in HFpEF patients.

SGLT2i reduces patient-reported HF symptom burden in HFrEF

News - June 30, 2020

HFA Discoveries These analyses of patient-reported outcomes in EMPERIAL trials suggest a trend towards reductions in HF symptom burden with empagliflozin compared to placebo in HFrEF patients.

80 mg tafamidis reduces mortality compared to 20 mg in ATTR-CM patients

News - June 29, 2020

HFA Discoveries An analysis of pooled data of the ATTR-ACT trial and a long-term extension study demonstrated reduction in mortality in ATTR-CM patients on 80 mg tafamidis compared to those on 20 mg.